Pfizer Inc (PFIZ34) — Cash Flow-to-Debt Ratio
Pfizer Inc (PFIZ34) has a Cash Flow-to-Debt Ratio of 0.01x as of June 2026, meaning its operating cash flow of R$835.00 Million could theoretically repay 0% of its total liabilities (R$115.64 Billion) in one year. See Pfizer Inc (PFIZ34) flexibility index to measure the company's free cash flow as a share of total liabilities.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Pfizer Inc Cash Flow-to-Debt Ratio (2014–2025)
Historical debt coverage capacity for Pfizer Inc across 12 annual periods. For the full cash flow conversion analysis, see cash efficiency ratio of Pfizer Inc.
Annual Cash Flow-to-Debt Ratio for Pfizer Inc (2014–2025)
Year-by-year debt coverage analysis for Pfizer Inc. Check PFIZ34 cash to earnings ratio to evaluate the quality of earnings relative to operating cash generation.
| Year | CF-to-Debt Ratio | Operating CF (BRL) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | 0.10x | R$11.71 Billion | R$121.39 Billion | ▼ -5.5% |
| 2024 | 0.10x | R$12.74 Billion | R$124.90 Billion | ▲ +16.3% |
| 2023 | 0.09x | R$12.04 Billion | R$137.21 Billion | ▼ -69.6% |
| 2022 | 0.29x | R$29.27 Billion | R$101.55 Billion | ▼ -7.8% |
| 2021 | 0.31x | R$32.58 Billion | R$104.28 Billion | ▲ +97.4% |
| 2020 | 0.16x | R$14.40 Billion | R$90.99 Billion | ▲ +31.4% |
| 2019 | 0.12x | R$12.59 Billion | R$104.45 Billion | ▼ -26.9% |
| 2018 | 0.16x | R$15.83 Billion | R$96.02 Billion | ▼ -1.4% |
| 2017 | 0.17x | R$16.80 Billion | R$100.49 Billion | ▲ +15.7% |
| 2016 | 0.14x | R$16.19 Billion | R$112.07 Billion | ▲ +0.7% |
| 2015 | 0.14x | R$14.69 Billion | R$102.38 Billion | ▼ -19.4% |
| 2014 | 0.18x | R$17.08 Billion | R$95.94 Billion | — |